Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis
Abstract Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer, associated with high mortality. Immune checkpoint inhibitors (ICIs) have demonstrated long‐lasting efficiency for treating advanced MCC. Despite a good safety profile, ICI remain associated with non‐negligible...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.232 |
| _version_ | 1797435230965989376 |
|---|---|
| author | Clémence Bertold Laura Troin Madleen Chassang Thierry Passeron Jérôme Doyen Henri Montaudié Alexandra Picard‐Gauci |
| author_facet | Clémence Bertold Laura Troin Madleen Chassang Thierry Passeron Jérôme Doyen Henri Montaudié Alexandra Picard‐Gauci |
| author_sort | Clémence Bertold |
| collection | DOAJ |
| description | Abstract Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer, associated with high mortality. Immune checkpoint inhibitors (ICIs) have demonstrated long‐lasting efficiency for treating advanced MCC. Despite a good safety profile, ICI remain associated with non‐negligible risk of immune‐related adverse events (irAEs), which may require treatment discontinuation if they are severe. We report the case of a long‐lasting complete response to Avelumab after rechallenge in a patient with a metastatic MCC who became resistant to this anti‐Programmed cell Death Ligand 1 (anti‐PD‐L1) treatment and who presented severe neuromuscular toxicity during anti‐PD‐1 treatment with Pembrolizumab, without recurrence of the irAE. The potential specificity of therapeutic properties and irAEs of each ICI supports a personalized management of antitumoral immunogenic response and its adverse effects. |
| first_indexed | 2024-03-09T10:45:13Z |
| format | Article |
| id | doaj.art-244192f47e7e4833ab1c1440aa6f4cc5 |
| institution | Directory Open Access Journal |
| issn | 2768-6566 |
| language | English |
| last_indexed | 2024-03-09T10:45:13Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | JEADV Clinical Practice |
| spelling | doaj.art-244192f47e7e4833ab1c1440aa6f4cc52023-12-01T10:43:27ZengWileyJEADV Clinical Practice2768-65662023-12-012494094310.1002/jvc2.232Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositisClémence Bertold0Laura Troin1Madleen Chassang2Thierry Passeron3Jérôme Doyen4Henri Montaudié5Alexandra Picard‐Gauci6Department of Dermatology, CHU Nice Université Côte d'Azur Nice FranceDepartment of Dermatology, CHU Nice Université Côte d'Azur Nice FranceDepartment of Radiology, CHU Nice Université Côte d'Azur Nice FranceDepartment of Dermatology, CHU Nice Université Côte d'Azur Nice FranceDepartment of radiation oncology of Radiotherapy, Centre Antoine‐Lacassagne Université Côte d'Azur Nice FranceDepartment of Dermatology, CHU Nice Université Côte d'Azur Nice FranceDepartment of Dermatology, CHU Nice Université Côte d'Azur Nice FranceAbstract Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer, associated with high mortality. Immune checkpoint inhibitors (ICIs) have demonstrated long‐lasting efficiency for treating advanced MCC. Despite a good safety profile, ICI remain associated with non‐negligible risk of immune‐related adverse events (irAEs), which may require treatment discontinuation if they are severe. We report the case of a long‐lasting complete response to Avelumab after rechallenge in a patient with a metastatic MCC who became resistant to this anti‐Programmed cell Death Ligand 1 (anti‐PD‐L1) treatment and who presented severe neuromuscular toxicity during anti‐PD‐1 treatment with Pembrolizumab, without recurrence of the irAE. The potential specificity of therapeutic properties and irAEs of each ICI supports a personalized management of antitumoral immunogenic response and its adverse effects.https://doi.org/10.1002/jvc2.232immune checkpoint inhibitorsimmune‐related adverse eventsimmunotherapymetastatic Merkel cell carcinomarechallenge |
| spellingShingle | Clémence Bertold Laura Troin Madleen Chassang Thierry Passeron Jérôme Doyen Henri Montaudié Alexandra Picard‐Gauci Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis JEADV Clinical Practice immune checkpoint inhibitors immune‐related adverse events immunotherapy metastatic Merkel cell carcinoma rechallenge |
| title | Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis |
| title_full | Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis |
| title_fullStr | Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis |
| title_full_unstemmed | Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis |
| title_short | Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis |
| title_sort | successful rechallenge with avelumab in a patient with advanced merkel cell carcinoma who presented pembrolizumab induced myositis |
| topic | immune checkpoint inhibitors immune‐related adverse events immunotherapy metastatic Merkel cell carcinoma rechallenge |
| url | https://doi.org/10.1002/jvc2.232 |
| work_keys_str_mv | AT clemencebertold successfulrechallengewithavelumabinapatientwithadvancedmerkelcellcarcinomawhopresentedpembrolizumabinducedmyositis AT lauratroin successfulrechallengewithavelumabinapatientwithadvancedmerkelcellcarcinomawhopresentedpembrolizumabinducedmyositis AT madleenchassang successfulrechallengewithavelumabinapatientwithadvancedmerkelcellcarcinomawhopresentedpembrolizumabinducedmyositis AT thierrypasseron successfulrechallengewithavelumabinapatientwithadvancedmerkelcellcarcinomawhopresentedpembrolizumabinducedmyositis AT jeromedoyen successfulrechallengewithavelumabinapatientwithadvancedmerkelcellcarcinomawhopresentedpembrolizumabinducedmyositis AT henrimontaudie successfulrechallengewithavelumabinapatientwithadvancedmerkelcellcarcinomawhopresentedpembrolizumabinducedmyositis AT alexandrapicardgauci successfulrechallengewithavelumabinapatientwithadvancedmerkelcellcarcinomawhopresentedpembrolizumabinducedmyositis |